See more : Itec Corporation (9964.T) Income Statement Analysis – Financial Results
Complete financial analysis of Stealth BioTherapeutics Corp (MITO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stealth BioTherapeutics Corp, a leading company in the Biotechnology industry within the Healthcare sector.
- Econach Holdings Co.,Ltd. (3521.T) Income Statement Analysis – Financial Results
- PFA Invest Kreditobligationer (PFIKRB.CO) Income Statement Analysis – Financial Results
- SportsHero Limited (SHO.AX) Income Statement Analysis – Financial Results
- Forte Biosciences, Inc. (FBRX) Income Statement Analysis – Financial Results
- Endeavour Mining plc (EDV.L) Income Statement Analysis – Financial Results
Stealth BioTherapeutics Corp (MITO)
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.56M | 29.31M | 44.60M | 53.06M | 63.22M | 48.45M |
| General & Administrative | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Cost & Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Interest Income | 3.00K | 139.00K | 988.00K | 195.09K | 56.84K | 799.02K |
| Interest Expense | 1.24M | 1.81M | 6.67M | 21.36M | 3.28M | 0.00 |
| Depreciation & Amortization | 77.00K | 232.00K | 284.00K | 309.04K | 346.87K | 312.54K |
| EBITDA | -51.21M | -55.42M | -64.78M | -75.05M | -79.28M | -60.74M |
| EBITDA Ratio | 0.00% | 0.00% | -307.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -51.29M | -48.67M | -45.83M | -75.28M | -79.72M | -61.85M |
| Operating Income Ratio | 0.00% | 0.00% | -217.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.22M | -8.79M | -25.90M | -21.43M | -3.19M | 799.02K |
| Income Before Tax | -52.53M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | -6.98M | -19.23M | -76.21K | 92.30K | 799.02K |
| Net Income | -53.77M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Net Income Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| EPS | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| EPS Diluted | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| Weighted Avg Shares Out | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
| Weighted Avg Shares Out (Dil) | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021
MITO Stock: Why It Is Trading Higher
Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences
Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences
Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate
Source: https://incomestatements.info
Category: Stock Reports